Duality Advisers’s Ascendis Pharma A/S ASND Stock Holding History

Duality Advisers’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,683	Closed	-$1M	–	575
2023 Q3	$1M	Buy	10,683 +4,595	+75%	+$430K	0.12%	288
2023 Q2	$543K	Buy	+6,088	New	+$530K	0.07%	379
2022 Q1	–	Sell	-2,526	Closed	-$340K	–	627
2021 Q4	$340K	Buy	+2,526	New	+$376K	0.04%	435
2021 Q3	–	Sell	-5,439	Closed	-$716K	–	525
2021 Q2	$716K	Sell	5,439 -3,955	-42%	-$527K	0.06%	390
2021 Q1	$1.21M	Buy	9,394 +6,286	+202%	+$955K	0.11%	308
2020 Q4	$518K	Buy	+3,108	New	+$514K	0.04%	441

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Duality Advisers's ASND Position: Q4 2023 in Review

Duality Advisers sold out of Ascendis Pharma A/S (ASND) in Q4 2023, closing a stake of 10,683 shares — an estimated $1M sold.

Duality Advisers first reported a position in ASND in Q4 2020 and held it in 6 quarters. The position peaked at $1.21M in Q1 2021. 185 funds tracked by Wall St. Rank hold ASND as of Q4 2023.

Duality Advisers reported no remaining Ascendis Pharma A/S position as of Q4 2023 after selling out during the quarter.
Duality Advisers sold 10,683 Ascendis Pharma A/S shares in Q4 2023, an estimated $1M.
Duality Advisers first reported a position in Ascendis Pharma A/S in Q4 2020 and held it in 6 quarters.
Duality Advisers's Ascendis Pharma A/S position peaked at $1.21M in Q1 2021.
185 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2023.

Based on Duality Advisers's 13F filing for Q4 2023, filed 1 Feb 2024.